newsfilter
← Latest News
PR Newswire·

BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction

VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (CSE:BIOV) (FRA: 5LB) (OTC:BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with B